Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene Participates in New Cancer Research Consortium
information fournie par Boursorama CP 01/09/2021 à 17:45
Ajoutez Boursorama à vos sources préférées

International Research Consortium Aims to Build a Reproducible Single-cell Sequencing Workflow to Capture Tumor Drug Persistence

Strasbourg (France) and Utrecht (The Netherlands), September 1st, 2021, 05:45 pm CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.

This collaborative research program aims to provide the cancer research community with a new gold standard workflow for single-cell sequencing by developing and validating best practices as well as generating and analysing high-quality data. The project aims to empower the scientific community to unravel drug resistance and develop smarter therapeutic strategies to better treat cancer and prevent resistance. PERSIST-SEQ is a five-year public-private partnership, funded by the Innovative Medicines Initiative (IMI), and led by the Oncode Institute and AstraZeneca.

Valeurs associées

TRANSGENE
0,8060 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
BIOPHYTIS
0,0869 +9,72%
CAC 40
8 457,02 +0,05%
ATON
0,0198 +16,47%
Pétrole Brent
89,36 -2,87%
HAFFNER ENERGY
0,574 -0,17%
Chargement...

Pages les plus populaires

L'offre BoursoBank